Publications by authors named "Daisuke Fukagawa"
Article Synopsis
- * Bevacizumab beyond PD (BBP) has shown to extend overall survival in recurrent colorectal cancer and prolong progression-free survival in recurrent breast and lung cancers.
- * Two key studies, MITO16/MaNGO-OV2B and JGOG3023, evaluated BBP for ovarian cancer, indicating its potential to improve treatment outcomes for patients with difficult-to-treat cases.
Article Synopsis
- - Cervical cancer is the fourth most common cancer among women globally, with advancements in treatment through angiogenesis inhibitors but a median survival of only 16.8 months for advanced cases.
- - The current 5-year survival rate for all stages of cervical cancer stands at 68%, highlighting the need for better treatment options.
- - Immunotherapy has shown promise in various cancers and is being explored in cervical cancer, with ongoing clinical trials aimed at defining its future role in treatment.
Objective: Uterine carcinosarcoma (UCS) is a highly aggressive neoplasm that is composed of an intricate admixture of carcinomatous and sarcomatous elements. The relationship between UCS and the epithelial to mesenchymal transition (EMT) has been reported. In this study, we examined how expression of E-cadherin was associated with the expression of EMT-related proteins in UCS.
View Article and Find Full Text PDFRecent studies have shown that cancer-associated fibroblasts (CAFs) and the epithelial-mesenchymal transition (EMT) contribute to invasive and metastatic abilities of ovarian cancer (OC) cells. In the present study, we attempted to identify the role of CAF- and EMT-related proteins in OCs, including serous carcinoma, mucinous carcinoma, endometrioid carcinoma and clear cell carcinoma using an immunohistochemical approach. The following CAF-related markers were used: CD10, podoplanin, fibroblast activating protein (FAP), platelet derived growth factor receptor (PDGFRα), PDGFRβ, S100A4 and α-smooth muscle actin (α-SMA).
View Article and Find Full Text PDFArticle Synopsis
- A 57-year-old woman was diagnosed with a 13-cm multilocular cystic ovarian tumor identified as struma ovarii, showing distinct histological variations.
- Histological analysis revealed both differentiated (follicular patterns) and de-differentiated (trabecular and small solid nests) patterns, with immunohistochemical studies indicating a change in E-cadherin expression between these components.
- The study suggested that the transition from differentiated to de-differentiated tissue is linked to the loss of E-cadherin, possibly driven by increased ZEB1 expression, while noting no significant mutations in the tumor components.
Objective: This study aims to clarify the incidence of Aurora kinase A (Aurora-A) protein expression and its correlation with clinical parameters in ovarian clear cell carcinoma (OCCC) tumor tissues. In addition, we assessed the efficacy of ENMD-2076, a novel selective Aurora-A inhibitor, in combination with chemotherapeutic agents for the treatment of OCCC.
Methods/materials: Aurora-A protein expression was determined by immunohistochemical staining of OCCC specimens from 56 patients to evaluate its correlation with clinical outcomes in OCCC.